bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Fig. S2 from FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis
Authors: Su Dan , Wang Ruobing , Chen Guangyu , Ding Chen , Liu Yueze , Tao Jinxin , Wang Yuanyang , Qiu Jiangdong , Luo Wenhao , Weng Guihu , Yang Gang , Zhang Taiping
Published: August 2024

Supplementary Fig. S2
Supplementary Fig. S19 from FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis
Authors: Su Dan , Wang Ruobing , Chen Guangyu , Ding Chen , Liu Yueze , Tao Jinxin , Wang Yuanyang , Qiu Jiangdong , Luo Wenhao , Weng Guihu , Yang Gang , Zhang Taiping
Published: August 2024

Supplementary Fig. S19
Supplementary Fig. S17 from FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis
Authors: Su Dan , Wang Ruobing , Chen Guangyu , Ding Chen , Liu Yueze , Tao Jinxin , Wang Yuanyang , Qiu Jiangdong , Luo Wenhao , Weng Guihu , Yang Gang , Zhang Taiping
Published: August 2024

Supplementary Fig. S17
Supplementary Fig. S1 from FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis
Authors: Su Dan , Wang Ruobing , Chen Guangyu , Ding Chen , Liu Yueze , Tao Jinxin , Wang Yuanyang , Qiu Jiangdong , Luo Wenhao , Weng Guihu , Yang Gang , Zhang Taiping
Published: August 2024

Supplementary Fig. S1
Data from CENP-E Inhibition Induces Chromosomal Instability and Synergizes with Diverse Microtubule-Targeting Agents in Breast Cancer
Authors: Tucker John B. , Carlsen Caleb L. , Scribano Christina M. , Pattaswamy Srishrika M. , Burkard Mark E. , Weaver Beth A.
Published: August 2024

Abstract
Drugs that perturb microtubules are commonly used to treat breast cancers of all subtypes in both early stage and metastatic disease, but they are effective in only approximately 50% of patients. High concentrations of microtubule-targeting agents can elicit mitotic arrest in cell culture models; however, recent evidence from primary and metastatic breast cancers has revealed that these agents only accumulate at intratumoral levels capable of inducing abnormal multipolar mitotic spindles, not mitotic arrest. Although the maintenance of multipolar spindles can generate cytotoxic rates of chromosomal instability (CIN), focusing of aberrant multipolar spindles into normal bipolar spindles can dramatically reduce CIN and confer resistance to microtubule poisons. Here, we showed that inhibition of the mitotic kinesin centromeric-associated protein-E (CENP-E) overcomes resistance caused by focusing multipolar spindles. Clinically relevant microtubule-targeting agents used a mechanistically conserved pathway to induce multipolar spindles without requiring centrosome amplification. Focusing could occur at any point in mitosis, with earlier focusing conferring greater resistance to antimicrotubule agents. CENP-E inhibition increased CIN on focused spindles by generating chromosomes that remained misaligned at spindle poles during anaphase, which substantially increased death in the resulting daughter cells. CENP-E inhibition synergized with diverse, clinically relevant microtubule poisons to potentiate cell death in cell lines and suppress tumor growth in orthotopic tumor models. These results suggest that primary resistance to microtubule-targeting drugs can be overcome by simultaneous inhibition of CENP-E.

Significance: The increased incidence of polar chromosomes induced by inhibition of the mitotic kinesin CENP-E exacerbates chromosomal instability, reduces daughter cell viability, and improves sensitivity to microtubule-targeting therapies.
Data from FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis
Authors: Su Dan , Wang Ruobing , Chen Guangyu , Ding Chen , Liu Yueze , Tao Jinxin , Wang Yuanyang , Qiu Jiangdong , Luo Wenhao , Weng Guihu , Yang Gang , Zhang Taiping
Published: August 2024

Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related death worldwide, primarily due to its rapid progression. The current treatment options for PDAC are limited, and a better understanding of the underlying mechanisms responsible for PDAC progression is required to identify improved therapeutic strategies. In this study, we identified FBXO32 as an oncogenic driver in PDAC. FBXO32 was aberrantly upregulated in PDAC, and high FBXO32 expression was significantly associated with an unfavorable prognosis in patients with PDAC. FRG1 deficiency promoted FBXO32 upregulation in PDAC. FBXO32 promoted cell migration and invasion in vitro and tumor growth and metastasis in vivo. Mechanistically, FBXO32 directly interacted with eEF1A1 and promoted its polyubiquitination at the K273 site, leading to enhanced activity of eEF1A1 and increased protein synthesis in PDAC cells. Moreover, FBXO32-catalyzed eEF1A1 ubiquitination boosted the translation of ITGB5 mRNA and activated focal adhesion kinase (FAK) signaling, thereby facilitating focal adhesion assembly and driving PDAC progression. Importantly, interfering with the FBXO32–eEF1A1 axis or pharmaceutical inhibition of FAK by defactinib, an FDA-approved FAK inhibitor, substantially inhibited PDAC growth and metastasis driven by aberrantly activated FBXO32–eEF1A1 signaling. Overall, this study uncovers a mechanism by which PDAC cells rely on FBXO32-mediated eEF1A1 activation to drive progression and metastasis. FBXO32 may serve as a promising biomarker for selecting eligible patients with PDAC for treatment with defactinib.

Significance: FBXO32 upregulation in pancreatic cancer induced by FRG1 deficiency increases eEF1A1 activity to promote ITGB5 translation and stimulate FAK signaling, driving cancer progression and sensitizing tumors to the FAK inhibitor defactinib.
An Immunometabolic Route for Activating cGAS/STING to Drive Anticancer Immunity
Authors: Borges Francisca , Garg Abhishek D.
Published: August 2024

The cGAS/STING pathway is a crucial immune activator in cancer biology, triggering innate immunosurveillance against tumors by sensing and reacting to endogenous mitochondrial DNA (mtDNA). In this issue of Cancer Research, research by Saha and colleagues highlights the significant impact of serine deprivation on this pathway, thereby unveiling its potential for anticancer therapy. Serine is essential for cellular metabolism and influences tumor growth and immune responses. Depriving cells of serine caused mitochondrial dysfunction and the release of mtDNA into the cytosol, activating the cGAS/STING pathway and inducing type I IFN responses. In mouse models, serine deprivation enhanced antitumor immunity, with increased tumoral immune infiltration, including CD4+/CD8+ T cells and type I IFN responses. Clinically, a genetic signature indicative of lower serine enrichment in colorectal cancer patients correlated with immune activation and improved survival. Furthermore, combining serine deprivation with PD1 blockade significantly reduced tumor volume and led to long-term immunity in mice, suggesting that serine depletion enhances the efficacy of immune checkpoint blockade. These findings propose serine deprivation as a promising strategy to boost antitumor immunity and improve cancer patient outcomes.

See related article by Saha et al., p. 2645
Supplementary Data 1 from Early Evaluation of Risk Stratification and Clinical Outcomes for Patients with Advanced Breast Cancer through Combined Monitoring of Baseline Circulating Tumor Cells and DNA
Authors: Zhang Qiang , Cai Zheng , Gerratana Lorenzo , Davis Andrew A. , D’Amico Paolo , Chawla Akhil , Jacob Saya , Zhang Youbin , Jiao Jianhua , Qin Weijun , Reduzzi Carolina , Flaum Lisa , Shah Ami , Gradishar William J.
Published: August 2024

Details for Figure 4A
Supplemental Table S2 from T2-FLAIR Mismatch Sign Predicts DNA Methylation Subclass and CDKN2A/B Status in IDH-Mutant Astrocytomas
Authors: Lee Matthew D. , Jain Rajan , Galbraith Kristyn , Chen Anna , Lieberman Evan , Patel Sohil H. , Placantonakis Dimitris G. , Zagzag David , Barbaro Marissa , Guillermo Prieto Eibl Maria del Pilar , Golfinos John G. , Orringer Daniel A. , Snuderl Matija
Published: August 2024

Supplemental Table S2. T2-weighted and FLAIR pulse sequence parameters
Supplemental Table S1 from T2-FLAIR Mismatch Sign Predicts DNA Methylation Subclass and CDKN2A/B Status in IDH-Mutant Astrocytomas
Authors: Lee Matthew D. , Jain Rajan , Galbraith Kristyn , Chen Anna , Lieberman Evan , Patel Sohil H. , Placantonakis Dimitris G. , Zagzag David , Barbaro Marissa , Guillermo Prieto Eibl Maria del Pilar , Golfinos John G. , Orringer Daniel A. , Snuderl Matija
Published: August 2024

Supplemental Table S1. MRI acquisition parameters
Table 2 from Urinary Metabolite Diagnostic and Prognostic Liquid Biopsy Biomarkers of Lung Cancer in Nonsmokers and Tobacco Smokers
Authors: Dalal Bhavik , Tada Takeshi , Patel Daxesh P. , Pine Sharon R. , Khan Mohammed , Oike Takahiro , Kanke Yasuyuki , Parker Amelia L. , Haznadar Majda , Toulabi Leila , Krausz Kristopher W. , Robles Ana I. , Bowman Elise D. , Gonzalez Frank J. , Harris Curtis C.
Published: August 2024

Univariate and multivariate regression analysis for factors associated with survival in nonsmokers from both cohorts.
Supplementary Table S7 from A Novel Approach to Quantify Heterogeneity of Intrahepatic Cholangiocarcinoma: The Hidden-Genome Classifier
Authors: Song Yi , Boerner Thomas , Drill Esther , Shin Paul , Kumar Sandeep , Sigel Carlie , Cercek Andrea , Kemeny Nancy , Abou-Alfa Ghassan , Iacobuzio-Donahue Christine , Cowzer Darren , Schultz Nikolaus , Walch Henry , Balachandran Vinod , Groot Koerkamp Bas , Kingham Peter , Soares Kevin , Wei Alice , D’Angelica Michael , Drebin Jeffrey , Chandwani Rohit , Harding James J. , Jarnagin William
Published: August 2024

Incidence of IDH1 mutations and FGF2 fusions in biliary-aligned intrahepatic cholangiocarcinoma (IHC) and hepatocellular carcinoma (HCC)-aligned IHC.
Supplementary Table S1 from Urinary Metabolite Diagnostic and Prognostic Liquid Biopsy Biomarkers of Lung Cancer in Nonsmokers and Tobacco Smokers
Authors: Dalal Bhavik , Tada Takeshi , Patel Daxesh P. , Pine Sharon R. , Khan Mohammed , Oike Takahiro , Kanke Yasuyuki , Parker Amelia L. , Haznadar Majda , Toulabi Leila , Krausz Kristopher W. , Robles Ana I. , Bowman Elise D. , Gonzalez Frank J. , Harris Curtis C.
Published: August 2024

The diagnostic efficiency of models in non-smoking exploratory and validation cohorts. LCC, Lung cancer cases; PC, Population controls; AUC, area under the curve; CI, confidence interval; SN, Sensitivity; SP, Specificity; NPV, negative predictive values; PPV, positive predictive values; CR, Creatine riboside; NANA- N-acetyl neuraminic acid.
Supplementary Figure S8 from Urinary Metabolite Diagnostic and Prognostic Liquid Biopsy Biomarkers of Lung Cancer in Nonsmokers and Tobacco Smokers
Authors: Dalal Bhavik , Tada Takeshi , Patel Daxesh P. , Pine Sharon R. , Khan Mohammed , Oike Takahiro , Kanke Yasuyuki , Parker Amelia L. , Haznadar Majda , Toulabi Leila , Krausz Kristopher W. , Robles Ana I. , Bowman Elise D. , Gonzalez Frank J. , Harris Curtis C.
Published: August 2024

Survival analysis for Non-smokers and Smokers by stage and histology. K-M plot for (A) Early-stage (I &II) Lung cancer cases; Late-stage (III & IV) Lung cancer cases and (B) LUAD cases; LUSC cases. NS, Non-smokers; SK, Smokers; LUAD, Lung adenocarcinoma; LUSC, Lung squamous cell carcinoma
Supplementary Table S3 from A Novel Approach to Quantify Heterogeneity of Intrahepatic Cholangiocarcinoma: The Hidden-Genome Classifier
Authors: Song Yi , Boerner Thomas , Drill Esther , Shin Paul , Kumar Sandeep , Sigel Carlie , Cercek Andrea , Kemeny Nancy , Abou-Alfa Ghassan , Iacobuzio-Donahue Christine , Cowzer Darren , Schultz Nikolaus , Walch Henry , Balachandran Vinod , Groot Koerkamp Bas , Kingham Peter , Soares Kevin , Wei Alice , D’Angelica Michael , Drebin Jeffrey , Chandwani Rohit , Harding James J. , Jarnagin William
Published: August 2024

Genetic pathway alterations.
Supplementary Figure S6 from Urinary Metabolite Diagnostic and Prognostic Liquid Biopsy Biomarkers of Lung Cancer in Nonsmokers and Tobacco Smokers
Authors: Dalal Bhavik , Tada Takeshi , Patel Daxesh P. , Pine Sharon R. , Khan Mohammed , Oike Takahiro , Kanke Yasuyuki , Parker Amelia L. , Haznadar Majda , Toulabi Leila , Krausz Kristopher W. , Robles Ana I. , Bowman Elise D. , Gonzalez Frank J. , Harris Curtis C.
Published: August 2024

Distribution of CR and NANA metabolite levels in (A) Exploratory cohort and (B) Validation cohort in male and female participants. **** p<0.0001; * p<0.05; LCC, lung cancer cases; NS, Non-smokers; x͂ = median
Supplementary Figure S4 from Urinary Metabolite Diagnostic and Prognostic Liquid Biopsy Biomarkers of Lung Cancer in Nonsmokers and Tobacco Smokers
Authors: Dalal Bhavik , Tada Takeshi , Patel Daxesh P. , Pine Sharon R. , Khan Mohammed , Oike Takahiro , Kanke Yasuyuki , Parker Amelia L. , Haznadar Majda , Toulabi Leila , Krausz Kristopher W. , Robles Ana I. , Bowman Elise D. , Gonzalez Frank J. , Harris Curtis C.
Published: August 2024

Distribution of CR and NANA metabolite levels in late-stage (III & IV) cases. **** p<0.0001, *** p<0.001; LS, late-stage (III & IV); x͂ = median
Supplementary Figure S3 from A Novel Approach to Quantify Heterogeneity of Intrahepatic Cholangiocarcinoma: The Hidden-Genome Classifier
Authors: Song Yi , Boerner Thomas , Drill Esther , Shin Paul , Kumar Sandeep , Sigel Carlie , Cercek Andrea , Kemeny Nancy , Abou-Alfa Ghassan , Iacobuzio-Donahue Christine , Cowzer Darren , Schultz Nikolaus , Walch Henry , Balachandran Vinod , Groot Koerkamp Bas , Kingham Peter , Soares Kevin , Wei Alice , D’Angelica Michael , Drebin Jeffrey , Chandwani Rohit , Harding James J. , Jarnagin William
Published: August 2024

Supplementary Figure S3 Overall survival stratified by biliary class in non-resected patients (A) and resected patients (B) without IDH1 mutations or FGFR2 fusion. Interaction between the presence of any IDH1 or FGFR2 mutation and the genomic classification was insignificant in both non-resected (p = 0.6) and resected patients (p = 0.5). See the main text for median survival estimates in each case.
Supplementary Figure S1 from Urinary Metabolite Diagnostic and Prognostic Liquid Biopsy Biomarkers of Lung Cancer in Nonsmokers and Tobacco Smokers
Authors: Dalal Bhavik , Tada Takeshi , Patel Daxesh P. , Pine Sharon R. , Khan Mohammed , Oike Takahiro , Kanke Yasuyuki , Parker Amelia L. , Haznadar Majda , Toulabi Leila , Krausz Kristopher W. , Robles Ana I. , Bowman Elise D. , Gonzalez Frank J. , Harris Curtis C.
Published: August 2024

Distribution of CR and NANA metabolite levels in non-smoker cases without and with (A) Childhood parental smoking exposure and (B) Secondhand smoking exposure. **** p<0.0001; NS, non-smokers; CPS, Childhood parental smoking exposure; SHS, Secondhand smoking exposure, LCC, lung cancer cases; x͂ = median
Figure 3 from Urinary Metabolite Diagnostic and Prognostic Liquid Biopsy Biomarkers of Lung Cancer in Nonsmokers and Tobacco Smokers
Authors: Dalal Bhavik , Tada Takeshi , Patel Daxesh P. , Pine Sharon R. , Khan Mohammed , Oike Takahiro , Kanke Yasuyuki , Parker Amelia L. , Haznadar Majda , Toulabi Leila , Krausz Kristopher W. , Robles Ana I. , Bowman Elise D. , Gonzalez Frank J. , Harris Curtis C.
Published: August 2024

K–M plots of the overall survival of lung cancer cases stratified by the median cutoff value of CR and NANA for nonsmokers in the (A) exploratory cohort and (B) validation cohort.
Supplementary Figure S3 from Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort
Authors: Corbaux Pauline , Freyer Gilles , Glehen Olivier , You Benoît , Bakrin Naoual , Gelot Audrey , Dayde David , Sajous Christophe , Piffoux Max , Péron Julien , Lescuyer Gaelle , Payen Lea , Kepenekian Vahan
Published: August 2024

Kinetics of plasmatic nucleosomes and CA125
Figure 1 from Urinary Metabolite Diagnostic and Prognostic Liquid Biopsy Biomarkers of Lung Cancer in Nonsmokers and Tobacco Smokers
Authors: Dalal Bhavik , Tada Takeshi , Patel Daxesh P. , Pine Sharon R. , Khan Mohammed , Oike Takahiro , Kanke Yasuyuki , Parker Amelia L. , Haznadar Majda , Toulabi Leila , Krausz Kristopher W. , Robles Ana I. , Bowman Elise D. , Gonzalez Frank J. , Harris Curtis C.
Published: August 2024

Box plots showing the distribution of CR and NANA urinary metabolite levels in the (A) exploratory cohort and (B) validation cohort were quantitatively measured by UPLC–MS/MS in the study participants. Kruskal–Wallis ANOVA; posthoc multiple comparisons, ****P < 0.0001; **P < 0.01. LCC, lung cancer cases; x͂ = median.
Supplementary Figure S2 from Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort
Authors: Corbaux Pauline , Freyer Gilles , Glehen Olivier , You Benoît , Bakrin Naoual , Gelot Audrey , Dayde David , Sajous Christophe , Piffoux Max , Péron Julien , Lescuyer Gaelle , Payen Lea , Kepenekian Vahan
Published: August 2024

Kaplan-Meier A. disease-free survival and B. overall survival curves according to platinum-sensitivity
Supplementary Figure S1 from Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort
Authors: Corbaux Pauline , Freyer Gilles , Glehen Olivier , You Benoît , Bakrin Naoual , Gelot Audrey , Dayde David , Sajous Christophe , Piffoux Max , Péron Julien , Lescuyer Gaelle , Payen Lea , Kepenekian Vahan
Published: August 2024

Trial flow chart
Table 2 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Authors: Saner Flurina A.M. , Takahashi Kazuaki , Budden Timothy , Pandey Ahwan , Ariyaratne Dinuka , Zwimpfer Tibor A. , Meagher Nicola S. , Fereday Sian , Twomey Laura , Pishas Kathleen I. , Hoang Therese , Bolithon Adelyn , Traficante Nadia , Alsop Kathryn , Christie Elizabeth L. , Kang Eun-Young , Nelson Gregg S. , Ghatage Prafull , Lee Cheng-Han , Riggan Marjorie J. , Alsop Jennifer , Beckmann Matthias W. , Boros Jessica , Brand Alison H. , Brooks-Wilson Angela , Carney Michael E. , Coulson Penny , Courtney-Brooks Madeleine , Cushing-Haugen Kara L. , Cybulski Cezary , El-Bahrawy Mona A. , Elishaev Esther , Erber Ramona , Gayther Simon A. , Gentry-Maharaj Aleksandra , Gilks C. Blake , Harnett Paul R. , Harris Holly R. , Hartmann Arndt , Hein Alexander , Hendley Joy , Hernandez Brenda Y. , Jakubowska Anna , Jimenez-Linan Mercedes , Jones Michael E. , Kaufmann Scott H. , Kennedy Catherine J. , Kluz Tomasz , Koziak Jennifer M. , Kristjansdottir Björg , Le Nhu D. , Lener Marcin , Lester Jenny , Lubiński Jan , Mateoiu Constantina , Orsulic Sandra , Ruebner Matthias , Schoemaker Minouk J. , Shah Mitul , Sharma Raghwa , Sherman Mark E. , Shvetsov Yurii B. , Soong T. Rinda , Steed Helen , Sukumvanich Paniti , Talhouk Aline , Taylor Sarah E. , Vierkant Robert A. , Wang Chen , Widschwendter Martin , Wilkens Lynne R. , Winham Stacey J. , Anglesio Michael S. , Berchuck Andrew , Brenton James D. , Campbell Ian , Cook Linda S. , Doherty Jennifer A. , Fasching Peter A. , Fortner Renée T. , Goodman Marc T. , Gronwald Jacek , Huntsman David G. , Karlan Beth Y. , Kelemen Linda E. , Menon Usha , Modugno Francesmary , Pharoah Paul D.P. , Schildkraut Joellen M. , Sundfeldt Karin , Swerdlow Anthony J. , Goode Ellen L. , DeFazio Anna , Köbel Martin , Ramus Susan J. , Bowtell David D.L. , Garsed Dale W.
Published: August 2024

Multivariate analysis of molecular alterations and OS in patients with HGSC and ENOC.
Supplementary Table S3 from Tissue-Free Liquid Biopsies Combining Genomic and Methylation Signals for Minimal Residual Disease Detection in Patients with Early Colorectal Cancer from the UK TRACC Part B Study
Authors: Slater Susanna , Bryant Annette , Aresu Maria , Begum Ruwaida , Chen Hsiang-Chi , Peckitt Clare , Lazaro-Alcausi Retchel , Carter Paul , Anandappa Gayathri , Khakoo Shelize , Melcher Lucinda , Potter Vanessa , Marti Francisca M. , Huang Joesph , Branagan Graham , George Nicol , Abulafi Muti , Duff Sarah , Raja Ashraf , Gupta Ashish , West Nicholas , Bucheit Leslie , Rich Thereasa , Chau Ian , Cunningham David , Starling Naureen
Published: August 2024

Baseline and postoperative characteristics by longitudinal ctDNA status in patients who recurred in the longitudinal analysis population (n=29)
Supplementary Table S7 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Authors: Saner Flurina A.M. , Takahashi Kazuaki , Budden Timothy , Pandey Ahwan , Ariyaratne Dinuka , Zwimpfer Tibor A. , Meagher Nicola S. , Fereday Sian , Twomey Laura , Pishas Kathleen I. , Hoang Therese , Bolithon Adelyn , Traficante Nadia , Alsop Kathryn , Christie Elizabeth L. , Kang Eun-Young , Nelson Gregg S. , Ghatage Prafull , Lee Cheng-Han , Riggan Marjorie J. , Alsop Jennifer , Beckmann Matthias W. , Boros Jessica , Brand Alison H. , Brooks-Wilson Angela , Carney Michael E. , Coulson Penny , Courtney-Brooks Madeleine , Cushing-Haugen Kara L. , Cybulski Cezary , El-Bahrawy Mona A. , Elishaev Esther , Erber Ramona , Gayther Simon A. , Gentry-Maharaj Aleksandra , Gilks C. Blake , Harnett Paul R. , Harris Holly R. , Hartmann Arndt , Hein Alexander , Hendley Joy , Hernandez Brenda Y. , Jakubowska Anna , Jimenez-Linan Mercedes , Jones Michael E. , Kaufmann Scott H. , Kennedy Catherine J. , Kluz Tomasz , Koziak Jennifer M. , Kristjansdottir Björg , Le Nhu D. , Lener Marcin , Lester Jenny , Lubiński Jan , Mateoiu Constantina , Orsulic Sandra , Ruebner Matthias , Schoemaker Minouk J. , Shah Mitul , Sharma Raghwa , Sherman Mark E. , Shvetsov Yurii B. , Soong T. Rinda , Steed Helen , Sukumvanich Paniti , Talhouk Aline , Taylor Sarah E. , Vierkant Robert A. , Wang Chen , Widschwendter Martin , Wilkens Lynne R. , Winham Stacey J. , Anglesio Michael S. , Berchuck Andrew , Brenton James D. , Campbell Ian , Cook Linda S. , Doherty Jennifer A. , Fasching Peter A. , Fortner Renée T. , Goodman Marc T. , Gronwald Jacek , Huntsman David G. , Karlan Beth Y. , Kelemen Linda E. , Menon Usha , Modugno Francesmary , Pharoah Paul D.P. , Schildkraut Joellen M. , Sundfeldt Karin , Swerdlow Anthony J. , Goode Ellen L. , DeFazio Anna , Köbel Martin , Ramus Susan J. , Bowtell David D.L. , Garsed Dale W.
Published: August 2024

Supplementary Table S7. Sequences of single guide RNAs used for CRISPR-mediated gene knockout.
Supplementary Results S1 from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study
Authors: Markussen Alice , Johansen Julia S. , Larsen Finn O. , Theile Susann , Hasselby Jane P. , Willemoe Gro L. , Lorentzen Torben , Madsen Kasper , Høgdall Estrid , Poulsen Tim S. , Wilken Eva E. , Geertsen Poul , Behrens Claus P. , Svane Inge M. , Nielsen Dorte , Chen Inna M.
Published: August 2024

Supplementary Results
Supplementary Table S5 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Authors: Saner Flurina A.M. , Takahashi Kazuaki , Budden Timothy , Pandey Ahwan , Ariyaratne Dinuka , Zwimpfer Tibor A. , Meagher Nicola S. , Fereday Sian , Twomey Laura , Pishas Kathleen I. , Hoang Therese , Bolithon Adelyn , Traficante Nadia , Alsop Kathryn , Christie Elizabeth L. , Kang Eun-Young , Nelson Gregg S. , Ghatage Prafull , Lee Cheng-Han , Riggan Marjorie J. , Alsop Jennifer , Beckmann Matthias W. , Boros Jessica , Brand Alison H. , Brooks-Wilson Angela , Carney Michael E. , Coulson Penny , Courtney-Brooks Madeleine , Cushing-Haugen Kara L. , Cybulski Cezary , El-Bahrawy Mona A. , Elishaev Esther , Erber Ramona , Gayther Simon A. , Gentry-Maharaj Aleksandra , Gilks C. Blake , Harnett Paul R. , Harris Holly R. , Hartmann Arndt , Hein Alexander , Hendley Joy , Hernandez Brenda Y. , Jakubowska Anna , Jimenez-Linan Mercedes , Jones Michael E. , Kaufmann Scott H. , Kennedy Catherine J. , Kluz Tomasz , Koziak Jennifer M. , Kristjansdottir Björg , Le Nhu D. , Lener Marcin , Lester Jenny , Lubiński Jan , Mateoiu Constantina , Orsulic Sandra , Ruebner Matthias , Schoemaker Minouk J. , Shah Mitul , Sharma Raghwa , Sherman Mark E. , Shvetsov Yurii B. , Soong T. Rinda , Steed Helen , Sukumvanich Paniti , Talhouk Aline , Taylor Sarah E. , Vierkant Robert A. , Wang Chen , Widschwendter Martin , Wilkens Lynne R. , Winham Stacey J. , Anglesio Michael S. , Berchuck Andrew , Brenton James D. , Campbell Ian , Cook Linda S. , Doherty Jennifer A. , Fasching Peter A. , Fortner Renée T. , Goodman Marc T. , Gronwald Jacek , Huntsman David G. , Karlan Beth Y. , Kelemen Linda E. , Menon Usha , Modugno Francesmary , Pharoah Paul D.P. , Schildkraut Joellen M. , Sundfeldt Karin , Swerdlow Anthony J. , Goode Ellen L. , DeFazio Anna , Köbel Martin , Ramus Susan J. , Bowtell David D.L. , Garsed Dale W.
Published: August 2024

Supplementary Table S5. Summary of cell lines used in this study.
Supplementary Data S2 from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study
Authors: Markussen Alice , Johansen Julia S. , Larsen Finn O. , Theile Susann , Hasselby Jane P. , Willemoe Gro L. , Lorentzen Torben , Madsen Kasper , Høgdall Estrid , Poulsen Tim S. , Wilken Eva E. , Geertsen Poul , Behrens Claus P. , Svane Inge M. , Nielsen Dorte , Chen Inna M.
Published: August 2024

Consort Checklist
Supplementary Data S1 from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study
Authors: Markussen Alice , Johansen Julia S. , Larsen Finn O. , Theile Susann , Hasselby Jane P. , Willemoe Gro L. , Lorentzen Torben , Madsen Kasper , Høgdall Estrid , Poulsen Tim S. , Wilken Eva E. , Geertsen Poul , Behrens Claus P. , Svane Inge M. , Nielsen Dorte , Chen Inna M.
Published: August 2024

Trial protocol
Supplementary Table S20 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Authors: Saner Flurina A.M. , Takahashi Kazuaki , Budden Timothy , Pandey Ahwan , Ariyaratne Dinuka , Zwimpfer Tibor A. , Meagher Nicola S. , Fereday Sian , Twomey Laura , Pishas Kathleen I. , Hoang Therese , Bolithon Adelyn , Traficante Nadia , Alsop Kathryn , Christie Elizabeth L. , Kang Eun-Young , Nelson Gregg S. , Ghatage Prafull , Lee Cheng-Han , Riggan Marjorie J. , Alsop Jennifer , Beckmann Matthias W. , Boros Jessica , Brand Alison H. , Brooks-Wilson Angela , Carney Michael E. , Coulson Penny , Courtney-Brooks Madeleine , Cushing-Haugen Kara L. , Cybulski Cezary , El-Bahrawy Mona A. , Elishaev Esther , Erber Ramona , Gayther Simon A. , Gentry-Maharaj Aleksandra , Gilks C. Blake , Harnett Paul R. , Harris Holly R. , Hartmann Arndt , Hein Alexander , Hendley Joy , Hernandez Brenda Y. , Jakubowska Anna , Jimenez-Linan Mercedes , Jones Michael E. , Kaufmann Scott H. , Kennedy Catherine J. , Kluz Tomasz , Koziak Jennifer M. , Kristjansdottir Björg , Le Nhu D. , Lener Marcin , Lester Jenny , Lubiński Jan , Mateoiu Constantina , Orsulic Sandra , Ruebner Matthias , Schoemaker Minouk J. , Shah Mitul , Sharma Raghwa , Sherman Mark E. , Shvetsov Yurii B. , Soong T. Rinda , Steed Helen , Sukumvanich Paniti , Talhouk Aline , Taylor Sarah E. , Vierkant Robert A. , Wang Chen , Widschwendter Martin , Wilkens Lynne R. , Winham Stacey J. , Anglesio Michael S. , Berchuck Andrew , Brenton James D. , Campbell Ian , Cook Linda S. , Doherty Jennifer A. , Fasching Peter A. , Fortner Renée T. , Goodman Marc T. , Gronwald Jacek , Huntsman David G. , Karlan Beth Y. , Kelemen Linda E. , Menon Usha , Modugno Francesmary , Pharoah Paul D.P. , Schildkraut Joellen M. , Sundfeldt Karin , Swerdlow Anthony J. , Goode Ellen L. , DeFazio Anna , Köbel Martin , Ramus Susan J. , Bowtell David D.L. , Garsed Dale W.
Published: August 2024

Supplementary Table S20. Immune cell type (LM22) absolute abundance in 126 primary HGSC tumors with CIBERSORTx.
Supplementary Figure 3 from Targeting GPC2 on Intraocular and CNS Metastatic Retinoblastomas with Local and Systemic Delivery of CAR T Cells
Authors: Pascual-Pasto Guillem , McIntyre Brendan , Giudice Anna M. , Alikarami Fatemeh , Morrissey Amanda , Matlaga Stephanie , Hofmann Ted J. , Burgueño Victor , Harvey Kyra , Martinez Daniel , Shah Amish C. , Foster Jessica B. , Pogoriler Jennifer , Eagle Ralph C. , Carcaboso Angel M. , Shields Carol L. , Leahey Ann-Marie , Bosse Kristopher R.
Published: August 2024

Supplementary Figure 3. Mouse retina expression of GPC2 and GD2, retinal CAR T-cell infiltration, systemic toxicities, and antigen loss in the intraocular model (see related main Fig. 4).
Supplementary Table S16 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Authors: Saner Flurina A.M. , Takahashi Kazuaki , Budden Timothy , Pandey Ahwan , Ariyaratne Dinuka , Zwimpfer Tibor A. , Meagher Nicola S. , Fereday Sian , Twomey Laura , Pishas Kathleen I. , Hoang Therese , Bolithon Adelyn , Traficante Nadia , Alsop Kathryn , Christie Elizabeth L. , Kang Eun-Young , Nelson Gregg S. , Ghatage Prafull , Lee Cheng-Han , Riggan Marjorie J. , Alsop Jennifer , Beckmann Matthias W. , Boros Jessica , Brand Alison H. , Brooks-Wilson Angela , Carney Michael E. , Coulson Penny , Courtney-Brooks Madeleine , Cushing-Haugen Kara L. , Cybulski Cezary , El-Bahrawy Mona A. , Elishaev Esther , Erber Ramona , Gayther Simon A. , Gentry-Maharaj Aleksandra , Gilks C. Blake , Harnett Paul R. , Harris Holly R. , Hartmann Arndt , Hein Alexander , Hendley Joy , Hernandez Brenda Y. , Jakubowska Anna , Jimenez-Linan Mercedes , Jones Michael E. , Kaufmann Scott H. , Kennedy Catherine J. , Kluz Tomasz , Koziak Jennifer M. , Kristjansdottir Björg , Le Nhu D. , Lener Marcin , Lester Jenny , Lubiński Jan , Mateoiu Constantina , Orsulic Sandra , Ruebner Matthias , Schoemaker Minouk J. , Shah Mitul , Sharma Raghwa , Sherman Mark E. , Shvetsov Yurii B. , Soong T. Rinda , Steed Helen , Sukumvanich Paniti , Talhouk Aline , Taylor Sarah E. , Vierkant Robert A. , Wang Chen , Widschwendter Martin , Wilkens Lynne R. , Winham Stacey J. , Anglesio Michael S. , Berchuck Andrew , Brenton James D. , Campbell Ian , Cook Linda S. , Doherty Jennifer A. , Fasching Peter A. , Fortner Renée T. , Goodman Marc T. , Gronwald Jacek , Huntsman David G. , Karlan Beth Y. , Kelemen Linda E. , Menon Usha , Modugno Francesmary , Pharoah Paul D.P. , Schildkraut Joellen M. , Sundfeldt Karin , Swerdlow Anthony J. , Goode Ellen L. , DeFazio Anna , Köbel Martin , Ramus Susan J. , Bowtell David D.L. , Garsed Dale W.
Published: August 2024

Supplementary Table S16. Median survival according to germline BRCA1 and BRCA2 status by RB1 protein expression.
Supplementary Table S1 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Authors: Saner Flurina A.M. , Takahashi Kazuaki , Budden Timothy , Pandey Ahwan , Ariyaratne Dinuka , Zwimpfer Tibor A. , Meagher Nicola S. , Fereday Sian , Twomey Laura , Pishas Kathleen I. , Hoang Therese , Bolithon Adelyn , Traficante Nadia , Alsop Kathryn , Christie Elizabeth L. , Kang Eun-Young , Nelson Gregg S. , Ghatage Prafull , Lee Cheng-Han , Riggan Marjorie J. , Alsop Jennifer , Beckmann Matthias W. , Boros Jessica , Brand Alison H. , Brooks-Wilson Angela , Carney Michael E. , Coulson Penny , Courtney-Brooks Madeleine , Cushing-Haugen Kara L. , Cybulski Cezary , El-Bahrawy Mona A. , Elishaev Esther , Erber Ramona , Gayther Simon A. , Gentry-Maharaj Aleksandra , Gilks C. Blake , Harnett Paul R. , Harris Holly R. , Hartmann Arndt , Hein Alexander , Hendley Joy , Hernandez Brenda Y. , Jakubowska Anna , Jimenez-Linan Mercedes , Jones Michael E. , Kaufmann Scott H. , Kennedy Catherine J. , Kluz Tomasz , Koziak Jennifer M. , Kristjansdottir Björg , Le Nhu D. , Lener Marcin , Lester Jenny , Lubiński Jan , Mateoiu Constantina , Orsulic Sandra , Ruebner Matthias , Schoemaker Minouk J. , Shah Mitul , Sharma Raghwa , Sherman Mark E. , Shvetsov Yurii B. , Soong T. Rinda , Steed Helen , Sukumvanich Paniti , Talhouk Aline , Taylor Sarah E. , Vierkant Robert A. , Wang Chen , Widschwendter Martin , Wilkens Lynne R. , Winham Stacey J. , Anglesio Michael S. , Berchuck Andrew , Brenton James D. , Campbell Ian , Cook Linda S. , Doherty Jennifer A. , Fasching Peter A. , Fortner Renée T. , Goodman Marc T. , Gronwald Jacek , Huntsman David G. , Karlan Beth Y. , Kelemen Linda E. , Menon Usha , Modugno Francesmary , Pharoah Paul D.P. , Schildkraut Joellen M. , Sundfeldt Karin , Swerdlow Anthony J. , Goode Ellen L. , DeFazio Anna , Köbel Martin , Ramus Susan J. , Bowtell David D.L. , Garsed Dale W.
Published: August 2024

Supplementary Table S1. Details of participating Ovarian Tumor Tissue Analysis (OTTA) consortium studies and ethics approvals.
Supplementary Figure S8 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Authors: Saner Flurina A.M. , Takahashi Kazuaki , Budden Timothy , Pandey Ahwan , Ariyaratne Dinuka , Zwimpfer Tibor A. , Meagher Nicola S. , Fereday Sian , Twomey Laura , Pishas Kathleen I. , Hoang Therese , Bolithon Adelyn , Traficante Nadia , Alsop Kathryn , Christie Elizabeth L. , Kang Eun-Young , Nelson Gregg S. , Ghatage Prafull , Lee Cheng-Han , Riggan Marjorie J. , Alsop Jennifer , Beckmann Matthias W. , Boros Jessica , Brand Alison H. , Brooks-Wilson Angela , Carney Michael E. , Coulson Penny , Courtney-Brooks Madeleine , Cushing-Haugen Kara L. , Cybulski Cezary , El-Bahrawy Mona A. , Elishaev Esther , Erber Ramona , Gayther Simon A. , Gentry-Maharaj Aleksandra , Gilks C. Blake , Harnett Paul R. , Harris Holly R. , Hartmann Arndt , Hein Alexander , Hendley Joy , Hernandez Brenda Y. , Jakubowska Anna , Jimenez-Linan Mercedes , Jones Michael E. , Kaufmann Scott H. , Kennedy Catherine J. , Kluz Tomasz , Koziak Jennifer M. , Kristjansdottir Björg , Le Nhu D. , Lener Marcin , Lester Jenny , Lubiński Jan , Mateoiu Constantina , Orsulic Sandra , Ruebner Matthias , Schoemaker Minouk J. , Shah Mitul , Sharma Raghwa , Sherman Mark E. , Shvetsov Yurii B. , Soong T. Rinda , Steed Helen , Sukumvanich Paniti , Talhouk Aline , Taylor Sarah E. , Vierkant Robert A. , Wang Chen , Widschwendter Martin , Wilkens Lynne R. , Winham Stacey J. , Anglesio Michael S. , Berchuck Andrew , Brenton James D. , Campbell Ian , Cook Linda S. , Doherty Jennifer A. , Fasching Peter A. , Fortner Renée T. , Goodman Marc T. , Gronwald Jacek , Huntsman David G. , Karlan Beth Y. , Kelemen Linda E. , Menon Usha , Modugno Francesmary , Pharoah Paul D.P. , Schildkraut Joellen M. , Sundfeldt Karin , Swerdlow Anthony J. , Goode Ellen L. , DeFazio Anna , Köbel Martin , Ramus Susan J. , Bowtell David D.L. , Garsed Dale W.
Published: August 2024

Supplementary Figure S8. Gene alterations across BRCA and RB1 altered subgroups.
Supplementary Figure S5 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Authors: Saner Flurina A.M. , Takahashi Kazuaki , Budden Timothy , Pandey Ahwan , Ariyaratne Dinuka , Zwimpfer Tibor A. , Meagher Nicola S. , Fereday Sian , Twomey Laura , Pishas Kathleen I. , Hoang Therese , Bolithon Adelyn , Traficante Nadia , Alsop Kathryn , Christie Elizabeth L. , Kang Eun-Young , Nelson Gregg S. , Ghatage Prafull , Lee Cheng-Han , Riggan Marjorie J. , Alsop Jennifer , Beckmann Matthias W. , Boros Jessica , Brand Alison H. , Brooks-Wilson Angela , Carney Michael E. , Coulson Penny , Courtney-Brooks Madeleine , Cushing-Haugen Kara L. , Cybulski Cezary , El-Bahrawy Mona A. , Elishaev Esther , Erber Ramona , Gayther Simon A. , Gentry-Maharaj Aleksandra , Gilks C. Blake , Harnett Paul R. , Harris Holly R. , Hartmann Arndt , Hein Alexander , Hendley Joy , Hernandez Brenda Y. , Jakubowska Anna , Jimenez-Linan Mercedes , Jones Michael E. , Kaufmann Scott H. , Kennedy Catherine J. , Kluz Tomasz , Koziak Jennifer M. , Kristjansdottir Björg , Le Nhu D. , Lener Marcin , Lester Jenny , Lubiński Jan , Mateoiu Constantina , Orsulic Sandra , Ruebner Matthias , Schoemaker Minouk J. , Shah Mitul , Sharma Raghwa , Sherman Mark E. , Shvetsov Yurii B. , Soong T. Rinda , Steed Helen , Sukumvanich Paniti , Talhouk Aline , Taylor Sarah E. , Vierkant Robert A. , Wang Chen , Widschwendter Martin , Wilkens Lynne R. , Winham Stacey J. , Anglesio Michael S. , Berchuck Andrew , Brenton James D. , Campbell Ian , Cook Linda S. , Doherty Jennifer A. , Fasching Peter A. , Fortner Renée T. , Goodman Marc T. , Gronwald Jacek , Huntsman David G. , Karlan Beth Y. , Kelemen Linda E. , Menon Usha , Modugno Francesmary , Pharoah Paul D.P. , Schildkraut Joellen M. , Sundfeldt Karin , Swerdlow Anthony J. , Goode Ellen L. , DeFazio Anna , Köbel Martin , Ramus Susan J. , Bowtell David D.L. , Garsed Dale W.
Published: August 2024

Supplementary Figure S5. Cell proliferation and cell cycle distribution of HGSC cell lines with RB1 knockout.
Supplementary Figure S2 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Authors: Saner Flurina A.M. , Takahashi Kazuaki , Budden Timothy , Pandey Ahwan , Ariyaratne Dinuka , Zwimpfer Tibor A. , Meagher Nicola S. , Fereday Sian , Twomey Laura , Pishas Kathleen I. , Hoang Therese , Bolithon Adelyn , Traficante Nadia , Alsop Kathryn , Christie Elizabeth L. , Kang Eun-Young , Nelson Gregg S. , Ghatage Prafull , Lee Cheng-Han , Riggan Marjorie J. , Alsop Jennifer , Beckmann Matthias W. , Boros Jessica , Brand Alison H. , Brooks-Wilson Angela , Carney Michael E. , Coulson Penny , Courtney-Brooks Madeleine , Cushing-Haugen Kara L. , Cybulski Cezary , El-Bahrawy Mona A. , Elishaev Esther , Erber Ramona , Gayther Simon A. , Gentry-Maharaj Aleksandra , Gilks C. Blake , Harnett Paul R. , Harris Holly R. , Hartmann Arndt , Hein Alexander , Hendley Joy , Hernandez Brenda Y. , Jakubowska Anna , Jimenez-Linan Mercedes , Jones Michael E. , Kaufmann Scott H. , Kennedy Catherine J. , Kluz Tomasz , Koziak Jennifer M. , Kristjansdottir Björg , Le Nhu D. , Lener Marcin , Lester Jenny , Lubiński Jan , Mateoiu Constantina , Orsulic Sandra , Ruebner Matthias , Schoemaker Minouk J. , Shah Mitul , Sharma Raghwa , Sherman Mark E. , Shvetsov Yurii B. , Soong T. Rinda , Steed Helen , Sukumvanich Paniti , Talhouk Aline , Taylor Sarah E. , Vierkant Robert A. , Wang Chen , Widschwendter Martin , Wilkens Lynne R. , Winham Stacey J. , Anglesio Michael S. , Berchuck Andrew , Brenton James D. , Campbell Ian , Cook Linda S. , Doherty Jennifer A. , Fasching Peter A. , Fortner Renée T. , Goodman Marc T. , Gronwald Jacek , Huntsman David G. , Karlan Beth Y. , Kelemen Linda E. , Menon Usha , Modugno Francesmary , Pharoah Paul D.P. , Schildkraut Joellen M. , Sundfeldt Karin , Swerdlow Anthony J. , Goode Ellen L. , DeFazio Anna , Köbel Martin , Ramus Susan J. , Bowtell David D.L. , Garsed Dale W.
Published: August 2024

Supplementary Figure S2. Representative immunohistochemical RB1 staining patterns.
Supplementary Figure S1 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Authors: Saner Flurina A.M. , Takahashi Kazuaki , Budden Timothy , Pandey Ahwan , Ariyaratne Dinuka , Zwimpfer Tibor A. , Meagher Nicola S. , Fereday Sian , Twomey Laura , Pishas Kathleen I. , Hoang Therese , Bolithon Adelyn , Traficante Nadia , Alsop Kathryn , Christie Elizabeth L. , Kang Eun-Young , Nelson Gregg S. , Ghatage Prafull , Lee Cheng-Han , Riggan Marjorie J. , Alsop Jennifer , Beckmann Matthias W. , Boros Jessica , Brand Alison H. , Brooks-Wilson Angela , Carney Michael E. , Coulson Penny , Courtney-Brooks Madeleine , Cushing-Haugen Kara L. , Cybulski Cezary , El-Bahrawy Mona A. , Elishaev Esther , Erber Ramona , Gayther Simon A. , Gentry-Maharaj Aleksandra , Gilks C. Blake , Harnett Paul R. , Harris Holly R. , Hartmann Arndt , Hein Alexander , Hendley Joy , Hernandez Brenda Y. , Jakubowska Anna , Jimenez-Linan Mercedes , Jones Michael E. , Kaufmann Scott H. , Kennedy Catherine J. , Kluz Tomasz , Koziak Jennifer M. , Kristjansdottir Björg , Le Nhu D. , Lener Marcin , Lester Jenny , Lubiński Jan , Mateoiu Constantina , Orsulic Sandra , Ruebner Matthias , Schoemaker Minouk J. , Shah Mitul , Sharma Raghwa , Sherman Mark E. , Shvetsov Yurii B. , Soong T. Rinda , Steed Helen , Sukumvanich Paniti , Talhouk Aline , Taylor Sarah E. , Vierkant Robert A. , Wang Chen , Widschwendter Martin , Wilkens Lynne R. , Winham Stacey J. , Anglesio Michael S. , Berchuck Andrew , Brenton James D. , Campbell Ian , Cook Linda S. , Doherty Jennifer A. , Fasching Peter A. , Fortner Renée T. , Goodman Marc T. , Gronwald Jacek , Huntsman David G. , Karlan Beth Y. , Kelemen Linda E. , Menon Usha , Modugno Francesmary , Pharoah Paul D.P. , Schildkraut Joellen M. , Sundfeldt Karin , Swerdlow Anthony J. , Goode Ellen L. , DeFazio Anna , Köbel Martin , Ramus Susan J. , Bowtell David D.L. , Garsed Dale W.
Published: August 2024

Supplementary Figure S1. Patients and tumor samples analyzed in this study.
Supplementary Table S1 - S10 from Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell–Mediated T-Cell Responses
Authors: van Eijck Casper W.F. , Haddaoui Hassana el , Kucukcelebi Songul , Vadgama Disha , Fellah Amine , Mustafa Dana A.M. , Aerts Joachim G.J.V. , van Eijck Casper H.J. , Willemsen Marcella
Published: August 2024

Supplementary Table S1. Antibodies used for flow cytometry analyses. Supplementary Table S2. Selected marker genes to identify immune cell type in the transcriptomic NanoString analysis.Supplementary Table S3. Summary of sample inclusion in various immunoprofiling analyses.Supplementary Table S4. Treatment characteristics of the included PDAC patients (n = 30).Supplementary Table S5. Univariate Cox proportional hazards models for OS and PFS of the clinical covariates.Supplementary Table S6. Clinical and treatment characteristics of the PDAC patients included in the flow cytometry analysis.Supplementary Table S7. Pathway overrepresentation analyses of the transcriptomic NanoString analysis. Genes with significant overexpression (P < 0.01) in baseline samples compared to after 12 rintatolimod infusions are included.Supplementary Table S8. Univariate Cox proportional hazards models for OS and PFS of the NanoString immune cell counts.Supplementary Table S9. Transcriptomic NanoString (A, B) and flowcytometry (C) immunoprofiling analysis comparing patients receiving ≤ and > median of 10 FOLFIRINOX cycles.Supplementary Table S10. Transcriptomic NanoString (A, B) and flowcytometry (C) immunoprofiling analysis comparing patients who did receive and did not receive SBRT.
Figure S1 from Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell–Mediated T-Cell Responses
Authors: van Eijck Casper W.F. , Haddaoui Hassana el , Kucukcelebi Songul , Vadgama Disha , Fellah Amine , Mustafa Dana A.M. , Aerts Joachim G.J.V. , van Eijck Casper H.J. , Willemsen Marcella
Published: August 2024

Supplementary Figure S1. Gating strategy of flow cytometry analyses on blood samples. Two panels were designed to investigate the presence and activation of peripheral T cells, DCs, and myeloid cells. The top-row gating strategy was applied in all panels.
Supplementary Data 2 from Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models
Authors: Gough Sheryl M. , Flanagan John J. , Teh Jessica , Andreoli Monica , Rousseau Emma , Pannone Melissa , Bookbinder Mark , Willard Ryan , Davenport Kim , Bortolon Elizabeth , Cadelina Gregory , Gordon Debbie , Pizzano Jennifer , Macaluso Jennifer , Soto Leofal , Corradi John , Digianantonio Katherine , Drulyte Ieva , Morgan Alicia , Quinn Connor , Békés Miklós , Ferraro Caterina , Chen Xin , Wang Gan , Dong Hanqing , Wang Jing , Langley David R. , Houston John , Gedrich Richard , Taylor Ian C.
Published: August 2024

Supplementary Tables S1-S4 and Figures S1-S16
Supplementary Tables 1 from Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study
Authors: Smithy James W. , Kalvin Hannah L. , Ehrich Fiona D. , Shah Ronak , Adamow Matthew , Raber Vladislav , Maher Collen A. , Kleman Jenna , McIntyre Deborah A.G. , Shoushtari Alexander N. , Betof Warner Allison , Callahan Margaret K. , Momtaz Parisa , Eton Omar , Nair Suresh , Wolchok Jedd D. , Chapman Paul B. , Berger Michael F. , Panageas Katherine S. , Postow Michael A.
Published: August 2024

Supplementary Tables
Supplementary Figures 1 from Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study
Authors: Smithy James W. , Kalvin Hannah L. , Ehrich Fiona D. , Shah Ronak , Adamow Matthew , Raber Vladislav , Maher Collen A. , Kleman Jenna , McIntyre Deborah A.G. , Shoushtari Alexander N. , Betof Warner Allison , Callahan Margaret K. , Momtaz Parisa , Eton Omar , Nair Suresh , Wolchok Jedd D. , Chapman Paul B. , Berger Michael F. , Panageas Katherine S. , Postow Michael A.
Published: August 2024

Supplementary Figures
Supplementary Table S3 from Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing Sarcoma
Authors: Jess Jennifer , Sorensen Katie M. , Boguslawski Elissa A. , Stout Matthew C. , Madaj Zachary B. , Caiello Benjamin P. , Pomaville Monica , Wilson Elizabeth R. , Kinn-Gurzo Seneca S. , Parker Curtis C. , Veluvolu Sridhar M. , Brysgel Taylor V. , Kaufman Rebecca , Kitchen-Goosen Susan M. , Gedminas Jenna M. , Grohar Patrick J.
Published: August 2024

Supplementary Table 3
Supplementary Table S2 from Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing Sarcoma
Authors: Jess Jennifer , Sorensen Katie M. , Boguslawski Elissa A. , Stout Matthew C. , Madaj Zachary B. , Caiello Benjamin P. , Pomaville Monica , Wilson Elizabeth R. , Kinn-Gurzo Seneca S. , Parker Curtis C. , Veluvolu Sridhar M. , Brysgel Taylor V. , Kaufman Rebecca , Kitchen-Goosen Susan M. , Gedminas Jenna M. , Grohar Patrick J.
Published: August 2024

Supplementary Table 2
Supplementary Table S1 from Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing Sarcoma
Authors: Jess Jennifer , Sorensen Katie M. , Boguslawski Elissa A. , Stout Matthew C. , Madaj Zachary B. , Caiello Benjamin P. , Pomaville Monica , Wilson Elizabeth R. , Kinn-Gurzo Seneca S. , Parker Curtis C. , Veluvolu Sridhar M. , Brysgel Taylor V. , Kaufman Rebecca , Kitchen-Goosen Susan M. , Gedminas Jenna M. , Grohar Patrick J.
Published: August 2024

Supplementary Table 1
Supplementary Figures S1-S15 from Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing Sarcoma
Authors: Jess Jennifer , Sorensen Katie M. , Boguslawski Elissa A. , Stout Matthew C. , Madaj Zachary B. , Caiello Benjamin P. , Pomaville Monica , Wilson Elizabeth R. , Kinn-Gurzo Seneca S. , Parker Curtis C. , Veluvolu Sridhar M. , Brysgel Taylor V. , Kaufman Rebecca , Kitchen-Goosen Susan M. , Gedminas Jenna M. , Grohar Patrick J.
Published: August 2024

Supplementary Figures S1-S15 and Legends
Supplementary Table S1 from Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers
Authors: Fischer-Riepe Lena , Kailayangiri Sareetha , Zimmermann Katharina , Pfeifer Rita , Aigner Michael , Altvater Bianca , Kretschmann Sascha , Völkl Simon , Hartley Jordan , Dreger Celine , Petry Katja , Bosio Andreas , von Döllen Angelika , Hartmann Wolfgang , Lode Holger , Görlich Dennis , Mackensen Andreas , Jungblut Melanie , Schambach Axel , Abken Hinrich , Rossig Claudia
Published: August 2024

Authentification of cell lines